HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2)
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Aug 3, 2023
app pub date -
Jun 2, 2021
filing date -
Jun 2, 2020
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Provided are novel human-derived monoclonal antibodies as well as antigen-binding fragments thereof which specifically recognize and preferably neutralize severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The anti-SARS-CoV-2 antibodies provided herein are useful in treating and diagnosis of COVID-19.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully